Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

R8404

Sigma-Aldrich

Rufinamide

≥98% (HPLC), powder

Synonym(s):

1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H8F2N4O
CAS Number:
106308-44-5
Molecular Weight:
238.19
MDL number:
MFCD00865314
UNSPSC Code:
12352200
PubChem Substance ID:
24724595
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: 9 mg/mL

originator

Novartis

storage temp.

−20°C

SMILES string

NC(=O)c1cn(Cc2c(F)cccc2F)nn1

InChI

1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)

InChI key

POGQSBRIGCQNEG-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Looking for similar products? Visit Product Comparison Guide

Application

Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.

Biochem/physiol Actions

Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Broad-spectrum anticonvulsant.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Diagnostic Implications

Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Warning

Hazard Statements

H336,H351,H361fd

Hazard Classifications

Carc. 2 - Repr. 2 - STOT SE 3

Target Organs

Central nervous system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Santiago Arroyo
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 4(1), 155-162 (2007-01-03)
Rufinamide is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs. Rufinamide was profiled for anticonvulsant activity at the National Institutes of Health and showed broad-spectrum anticonvulsant properties at nontoxic doses in animal models. The principal mechanism of action
Emma D Deeks et al.
CNS drugs, 20(9), 751-760 (2006-09-07)
Rufinamide, a triazole derivative, reduces the recovery capacity of neuronal sodium channels after inactivation, limiting neuronal sodium-dependent action potential firing and mediating anticonvulsant effects. In children, adolescents and adults, adjunctive oral rufinamide was more effective than placebo in treating seizures
Heather Ann Wier et al.
Paediatric drugs, 13(2), 97-106 (2011-03-01)
Rufinamide is a triazole derivative with broad-spectrum antiepileptic effects that is unrelated to any antiepileptic drug currently on the market. The European Commission and the US FDA approved rufinamide in 2007 and 2008, respectively, for adjunctive treatment of seizures associated
Paul L McCormack
PharmacoEconomics, 30(3), 247-256 (2012-02-16)
Rufinamide (Inovelon®), a triazole derivative, is an oral antiepileptic drug approved in the EU as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. The efficacy of oral rufinamide as adjunctive therapy
Rainer Schimpf et al.
Heart rhythm, 9(5), 776-781 (2012-01-17)
The arrhythmogenic potential of short QT intervals has recently been highlighted in patients with a short QT syndrome. Drug-induced QT-interval prolongation is a known risk factor for ventricular tachyarrhythmias. However, reports on drug-induced QT-interval shortening are rare and proarrhythmic effects
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service